SCHEMBL1195178

SCHEMBL1195178

COc1ccc(COCC2COC(C)(C)O2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.41
TRPV6 Q9H1D0 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
GLA P06280 1/20 0.40
IDO1 P14902 2/20 0.39
AGXT P21549 2/20 0.39
F10 P00742 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
CA1 P00915 1/20 0.38
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36
MMP13 P45452 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
APP P05067 3/20 0.36
PKM P14618 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4612615 1.00 CA2 (0.41) CA2TRPV6NPSR1GLAIDO1
SCHEMBL1195175 1.00 CA2 (0.41) CA2TRPV6NPSR1GLAIDO1
SCHEMBL13269812 0.86 L3MBTL1 (0.40) CA2NPSR1GLAIDO1AGXT
SCHEMBL26510718 0.86 CA2 (0.43) CA2NPSR1AGXTF10PKM
SCHEMBL7968239 0.84 CA2 (0.46) CA2NPSR1F10ALDH1A1TMEM97
SCHEMBL7968245 0.84 CA2 (0.46) CA2NPSR1F10ALDH1A1TMEM97
SCHEMBL17434412 0.84 CA2 (0.42) CA2NPSR1IDO1F10APP
SCHEMBL5606199 0.84 TMEM97 (0.48) CA2NPSR1F10L3MBTL1ALDH1A1
SCHEMBL2182755 0.84 TMEM97 (0.48) CA2NPSR1F10L3MBTL1ALDH1A1
SCHEMBL565818 0.84 TMEM97 (0.48) CA2NPSR1F10L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4321524-B1 LIPID AND COMPOSITION SOGO PHARM (JP) 2025-12-10 EP disclosed
EP-4635939-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING SAME Korea Institute of Science and Technology (KR) 2025-10-22 EP disclosed
US-20240226287-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-07-11 US disclosed
US-20240226287-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-07-11 US disclosed
US-20240226287-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-07-11 US disclosed
WO-2024128525-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING SAME 한국과학기술연구원 2024-06-20 WO disclosed
US-20240148664-A1 LIPID AND COMPOSITION SOGO PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
EP-4321524-A1 LIPID AND COMPOSITION Sogo Pharmaceutical Co., Ltd. (JP) 2024-02-14 EP disclosed
CN-117500819-A Lipid and composition 相互药工株式会社 2024-02-02 CN disclosed
WO-2022215758-A1 LIPID AND COMPOSITION 相互薬工株式会社 2022-10-13 WO disclosed
WO-2021038573-A1 DRUG CONTAINING TARGETING LIPOSOMES NEXTAR CHEMPHARMA SOLUTIONS LTD. (IL) 2021-03-04 WO disclosed
US-7887835-B2 for vascular lesion imaging and for diagnosing arteriosclerosis, ischemia with X-ray angiography and positron emission tomography; fluorinated steroid ester, glyceride compounds, phosphatidylcholine, and phosphatidylserine as membrane components of liposome FUJIFILM CORPORATION (JP) 2011-02-15 US disclosed
EP-1492776-B1 IODINATED TRIGLYCERIDE ANALOGS FUJIFILM CORP (JP) 2008-10-29 EP disclosed
US-20080138285-A1 Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound FUJIFILM CORPORATION (JP) 2008-06-12 US disclosed
US-7371877-B2 Glycerol ester derivative FUJIFILM CORPORATION (JP) 2008-05-13 US disclosed
EP-1916255-A2 Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound FUJIFILM Corporation (JP) 2008-04-30 EP disclosed
US-20060062726-A1 with iodophenyl group (radioisotope), as a membrane component of liposomes, which enables lesion-selective contrast X-ray radiography of a vascular disease; metabolized in the liver, not accumulated in living bodies FUJIFILM CORPORATION (JP) 2006-03-23 US disclosed
EP-1492776-A2 IODINATED TRIGLYCERIDE ANALOGS Fuji Photo Film Co. Ltd. (JP) 2005-01-05 EP disclosed
WO-2003080554-A2 IODINATED TRIGLYCERIDE ANALOGS FUJI PHOTO FILM CO., LTD. (JP) 2003-10-02 WO disclosed
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148664-A1 LIPID AND COMPOSITION PLIN3, PLIN1, FABP1 CA2 3102/4885TRPV6 3815/4885NPSR1 1609/4885
US-20080138285-A1 Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound PHOSPHO1, SGMS1, SGMS2 CA2 3022/4885TRPV6 670/4885NPSR1 1937/4885
US-20060062726-A1 with iodophenyl group (radioisotope), as a membrane component of liposomes, which enables lesion-selective contrast X-ray radiography of a vascular disease; metabolized in the liver, not accumulated in living bodies MSR1, LIPA, LIPC CA2 1088/4885TRPV6 1641/4885NPSR1 1373/4885
US-20240226287-A1 NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME HDLBP, LRAT, CETP CA2 4384/4885TRPV6 2254/4885NPSR1 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.